"Darunavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.
| Descriptor ID |
D000069454
|
| MeSH Number(s) |
D02.065.884.438 D02.241.081.251.222 D02.886.590.700.400 D03.383.312.303
|
| Concept/Terms |
TMC 114- TMC 114
- 114, TMC
- TMC114
- TMC-114
|
Below are MeSH descriptors whose meaning is more general than "Darunavir".
Below are MeSH descriptors whose meaning is more specific than "Darunavir".
This graph shows the total number of publications written about "Darunavir" by people in this website by year, and whether "Darunavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Darunavir" by people in Profiles.
-
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV. 2022 06; 9(6):e404-e413.
-
HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010 Oct; 54(10):4253-61.
-
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):614-8.
-
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010; 15(7):1045-52.